Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000968

Drug Information
NameNaproxen    
SynonymsUNII-57Y76R9ATQ; UPCMLD-DP001; (S)-()-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; KBio3_001567; Soproxen; Naproxi 250; Prestwick2_000791; 65126_FLUKA; SPECTRUM1500425; KBioGR_000597; Novonaprox; ARONIS24306; (S)-(+)-Naproxen; Naxopren; (S)-2-(6-Methoxy-2-naphthyl)propionic acid; NCGC00016759-01; Napflam; Prestwick0_000791; Naproxene [INN-French]; d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure [German]; 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (.alpha.S)-; (S)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid; NCGC00161591-01; Lopac0_000792; SPBio_002861; Spectrum_000977; Velsay; HMS500M04; UPCMLD-DP001:001; Fuxen; BIDD:GT0062; Prestwick1_000791; Patxen; Danaprox; SPBio_000966; d-2-(6-Methoxy-2-naphthyl)propionic acid; Sinton; TL8003659; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; FT-0082415; Congex; Duk; Naprelan; Narocin; BRD-K59197931-236-09-6; Nalyxan; NINDS_000242; Equiproxen; Naposin; Aleve; Apronax; Propionic acid, 2-(6-methoxy-2-naphthyl)-, (+)-; (S)-()-2-(6-Methoxy-2-naphthyl)propionic acid; Rahsen; Napratec; HMS2091H12; Clinosyn; Tohexen; CMWTZPSULFXXJA-VIFPVBQESA-; Leniartil; CAS-22204-53-1; (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Napmel; 22204-53-1; (+)-Naproxen; Proxen LE; Nafasol; Bonyl; Apo-Naproxen; Laraflex; Pronaxen; Noflam; Napren E; Genoxen; Arthrisil; Sinartrin; Spectrum5_001327; Naproxene; Naprius; (+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Lefaine; Floginax; Naprosyn LLE Forte; Axer; DivK1c_000242; Flexen; BSPBio_002067; Apo-Napro-NA; 284785_ALDRICH; CHEBI:7476; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)-; Equiproxen (Veterinary); Spectrum4_000069; (+)-2-(Methoxy-2-naphthyl)-propionsaeure; Sutony; MolPort-000-145-960; AC1Q4ET9; SR-01000075977-3; HMS1920P13; Calosen; Narma; d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure; Nycopren; Napxen; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)- (8CI); Saritilron; Atiflan; KBio2_006593; InChI=1/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1; (+)-2-(Methoxy-2-naphthyl)-propionic acid; Naxyn 500; Prexan; Reuxen; Naproxi 500; Naxyn; Naxen F; DB08298; (+)-2-(6-Methoxy-2-naphthyl)propionic acid; Vinsen; Headlon; 46482_RIEDEL; KBio1_000242; Artroxen; Naprosin; KBioSS_001457; (+)-2-(Methoxy-2-naphthyl)-propionsaeure [German]; AC1Q4F4H; Flanax Forte; AC-1363; (S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; BRD-K59197931-001-02-9; N8280_SIAL; Spectrum3_000514; Spectrum2_001043; Traumox; Naprontag; Napren; d-Naproxen; NAPROXEN; (S)-2-(6-Methoxy-2-naphthyl)propanoic acid; Acusprain; CHEMBL154; (+)NAPROXEN; Priaxen; Sutolin; EINECS 244-838-7; HMS2089N21; LS-124738; Methoxypropiocin; Naprosyn LLE; Flexipen; Roxen; Anaprox; NPS; KBio2_004025; M1021; CID156391; CCRIS 5265; Bipronyl; Prafena; Prestwick_349; Naproxenum [INN-Latin]; (S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Rheumaflex; Naproxen [USAN:BAN:INN:JAN]; AC1Q4F4I; (+)-(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Veradol; RS-3540; Naproxeno; (S)-Naproxen; Naxyn 250; Naprosyne; Xenar; Artagen; U-Ritis; RS 3540; IDI1_000242; Naxen; (+)-(S)-Naproxen; HSDB 3369; Dysmenalgit N; Anexopen; Naproxeno [INN-Spanish]; Artrixen; AC1L4G3X; Anax; Daprox; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (S)-; KBio2_001457; NCGC00021127-01; STOCK1N-50633; 46482_FLUKA; Proxen LLE; Ec-Naprosyn; CG 3117; Naproxenum    
Trade NameAnaprox; Antalgin; Flanax; Miranax; Naprelan; Naprogesic; Naprosyn;Narocin; Proxen; Synflex; Xenobid    
IndicationPain and Rheumatoid arthritisApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAnalgesics    
CAS NumberCAS 22204-53-1
FormularC14H14O3    
PubChem Compound IDCID 156391.    
PubChem Substance IDSID 173087.    
SuperDrug ATC IDG02CC02;    
SuperDrug CAS ID022204531;    
TargetCOX-2Inhibitor[2][3]
Ref 1New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. To Reference
Ref 2Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD). Expert Opin Biol Ther. 2009 May;9(5):649-57. To Reference
Ref 3Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543